Lantern Pharma advances TNBC and NSCLC trials, names interim CEO after Q3 2026
The company reported clinical site activation for LP-184 in breast cancer and Taiwan approval to open HARMONIC Part 2, alongside a CEO change and a $7.6 million cash balance.
SEC filing, FDA (4)